secwatch / observer
8-K filed January 8, 2024, 6:59 PM ET ticker BRKR CIK 0001109354
earnings confidence high sentiment positive materiality 0.75

Bruker prelim Q4 rev >$830M, FY2023 >$2.94B; guides 2024 above-market organic growth

BRUKER CORP

2023-FY EPS reported $2.90 revenue$2,964,500,000

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BRUKER CORP reported the full year 2023 results: revenue greater than $2.94 billion.

Period
the full year 2023
Revenue
greater than $2.94 billion
Result
preliminary results
Exact text from the filing
The Company also provided current preliminary expectation that revenue for the full year 2023 is greater than $2.94 billion, including organic revenue growth greater than 13% year-over-year.
View on SEC.gov
Earnings Releases SEC 8-K Item 2.02 confidence 0.9

BRUKER CORP reported the fourth quarter of 2023 results: revenue greater than $830 million.

Period
the fourth quarter of 2023
Revenue
greater than $830 million
Result
preliminary results
Exact text from the filing
On January 8, 2024, during its scheduled presentation at the 42nd Annual J.P. Morgan Healthcare Conference, Bruker Corporation (the “Company”) stated that its current preliminary expectation for revenue for the fourth quarter of 2023 is greater than $830 million including organic revenue growth greater than 12% year-over-year and that fourth quarter 2023 BSI bookings were solid.
View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

BRUKER CORP filing history →

Source: SEC EDGAR
accession 0000950170-24-002823
Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.